Atlas of Genetics and Cytogenetics in Oncology and Haematology

Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   
X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

INPP4B (Inositol Polyphosphate-4-Phosphate Type II B)

Written2017-04Hasan Huseyin Kazan, Ufuk Gunduz
Department of Biological Sciences, Middle East Technical University, Ankara, hasanhuseyinkazan@gmail.com ((HHK); Department of Biological Sciences, Middle East Technical University, Ankara, Turkey; ufukg@metu.edu.tr (UG)

Abstract Review on INPP4B, with data on DNA, on the protein encoded, and where the gene is implicated.

Keywords Inositol Polyphosphate-4-Phosphate Type II B (INPP4B), tumor suppressor, PI3K/AKT pathway

(Note : for Links provided by Atlas : click)

Identity

Alias_namesinositol polyphosphate-4-phosphatase, type II, 105kD
inositol polyphosphate-4-phosphatase, type II, 105kDa
Other alias
HGNC (Hugo) INPP4B
LocusID (NCBI) 8821
Atlas_Id 43320
Location 4q31.21; Start: 142,023,160 bp End: 142,847,432 bp; 824.273 bases; Orientation: Minus strand  [Link to chromosome band 4q31]
Location_base_pair Starts at 142023160 and ends at 142846535 bp from pter ( according to hg19-Feb_2009)  [Mapping INPP4B.png]
Local_order From centromere to telomere: LINC02276, IL15, INPP4B, LOC07986194, LOC100287014.
 
  Local order of INPP4B. Local order is shown together with leading and subsequent genes on chromosome 4. The direction of arrows indicates transcriptional directions on the chromosome and arrow sizes approximate gene sizes.
Fusion genes
(updated 2017)		Data from Atlas, Mitelman, Cosmic Fusion, Fusion Cancer, TCGA fusion databases with official HUGO symbols (see references in chromosomal bands)

DNA/RNA

Note Human INPP4B gene is about 824 kb, localized at 4q31.1 and minus oriented. There are 27 exons of human INPP4B; the first four exons and a part of exon 5 form 5' untranslated region (UTR). A huge part of exon 27 constitutes 3' UTR (Croft et al., 2017). Mouse Inpp4b consists of 25 exons with the size of 45 to 1340 nucleotides. Two of those exons are 5' untranslated. The entire mouse Inpp4b gene is 600 kb. Gene locus is remarkably conserved between human and mouse (Ferron and Vacher, 2006).
 
  Numbers and illustrative sizes of exons of human INPP4B. Red boxes are the coding region and black boxes are the non-coding ones. Data adapted from Croft et al., 2017.
Transcription In murine studies, an alternative-spliced form of cDNA, which was called Inpp4bαs and did not include exon 5 compared to Inpp4bα, was identified (Ferron and Vacher, 2006).
There are three identified transcript variants of human INPP4B. Variant 1 has 27 exons; variant 2 and 3 have 26. Transcript variant 1 of human INPP4B is 4.590 bp; variant 2 is 8.984 bp and variant 3 is 9.083 bp (NCBI, NM_001331040.1; NM_001101669.2; NM_003866.3). Variant 1 and 2 encode the same isoform but their 5' untranslated region (UTR) differ from each other. Variant 3 contains an alternative 3' coding region and a novel 3' UTR compared to variant 1 (NCBI, 2017). Recently, Croft et al. isolated a novel variant of INPP4B, called INNP4B-S. This variant was shown to include an extra 27 bp from the sequence between exon 15 and 16, called exon 15A. Also, exons 20-24 were illustrated to be spliced compared to previous variants (Croft et al., 2017). ).
In murine studies, transcription start site of Inpp4b was shown to be tissue specific (Ferron and Vacher, 2006). In human colon cancer cell lines, ETS1 was shown to regulate the expression of INPP4B by directly binding to promoter region of the gene (Guo et al., 2016).

Protein

Note There are two isoforms of INPP4B protein, called INPP4Bα and INPP4Bβ (Billclif and Lowe, 2014). Mouse Inpp4bα cDNA encodes a 927 amino acid protein while Inpp4bβ cDNA encodes a 941 amino acid protein with a molecular weight of ~105 kDa which is the same with that of human INPP4B protein (Uniprot: O15327). INPP4B consists of an N-terminal C2-lipid binding domain, Nervy Homology 2 (NHR2) domain and a C-terminal dual phosphatase domain including a conserved Cys(X)5Arg motif. NHR2 is responsible for oligomerization and protein-protein interaction (Agoulnik et al., 2011).
 
  Illustration of INPP4B protein. INPP4B protein consists of C2-lipid binding domain, Nervy Homology 2 (NHR2) domain and C-terminal dual phosphatase domain where conserved Cys(X)5Arg motif locates. Data adapted from Agoulnik et al., 2011.
Expression Inpp4bα has a broad tissue expression with higher levels in brain, skeletal muscle, lung, spleen, testis and thymus. Nevertheless, Inpp4bβ has a limited expression in brain, small intestine, skeletal muscle and heart (Ferron and Vacher, 2006).
 
  Expression profile of INPP4B in the tissues. INPP4B is moderately expressed in a numerous tissues including brain, muscles, pancreas, intestines, kidney, testis, prostate, breast and endometrium. Data taken from The Human Protein Atlas (http://www.proteinatlas.org) in April, 2017.
Localisation Alpha form of INPP4B and INPP4B-S localize in cytoplasm while beta form mainly localize in Golgi apparatus (Ferron and Vacher, 2006; Billcliff and Lowe, 2014; Croft et al., 2017).
Function Inositol polyphosphate 4-phosphate type II (INPP4B) is an enzyme responsible for phosphoinositide homeostasis. The major substrate for INPP4B is phophatidylinositol 3,4-biphosphate (PI(3,4)P2). PI(3,4)P2 is dephospharylated by INPP4B on D4 position and converted to phophatidylinositol 3-phosphate (PI(3)P). Those are critical secondary messengers in cells. Also, the substrate of INPP4B, PI(3,4)P2 is necessary for the activation of AKT. Thus, INPP4B is a negative regulator of PI3K/AKT signaling pathway. AKT is a potent driver of tumorigenic cell growth. Hence, INPP4B was at first proposed as a tumor suppressor protein. However, INPP4B was illustrated to activate serum glucocorticoid-regulated kinase 3 ( SGK3), which also promotes cellular proliferation and growth, via production of PI(3)P and in turn could be oncogenic (Chi et al., 2015; Guo et al., 2016). INPP4B was also demonstrated to have a role in nerve conduction velocity (Lemcke et al., 2014) and regulation of osteoclast differentiation (Ferron et al., 2011; Vacher, 2013). Moreover, INPP4B was shown to dephosphorylate phosphotyrosine analogs, paranitrophenyl phosphate (pNPP) and 6,8-difluoro-4-methylumbelliferyl (DifMUP), pointing that INPP4B has a protein tyrosine phosphatase activity (Lopez et al., 2013).
 
  Functions of INPP4B protein. INPP4B dephosphorylates PI(3,4)P2 to PI(3)P. PI(3,4)P2 is a secondary messenger which is important for activation of AKT to promote cell proliferation, survival, migration and invasion. Thus, INPP4B proposed as a tumor suppressor. However, the product of INPP4B, PI(3)P was shown to trigger activation of SGK3 which also promotes those phenotypes. So, INPP4B was further proved to be oncogenic. Besides, INPP4B is fundamental for the regulation of nerve conduction velocity and osteoclast differentiation. Data adapted from Chew et al., 2015b.
Homology Human and mouse INPP4B proteins share 96% identity. All mammalian INPP4B proteins include a Cys(X)5Arg phosphatase catalytic site and a conserved C2 domain (Ferron and Vacher, 2006). C2 lipid binding domain of INPP4B is 91% identical between human and mouse (Agoulnik et al., 2011).

Mutations

Note The C-terminal lipid phosphatase domain contains C 842KSAKDRT (aa 842-849) motif which is conserved between type I and II phosphatases. Mutation of cysteine at position 842 to alanine in this motif causes INPP4B to unable to dephosphorylate phosphatidylinositols (Agoulnik et al., 2011). Also, K846M mutation resulted in loss of lipid phosphatase activity without affecting protein phosphatase activity and D847E mutation caused to loss of protein phosphatase activity and decrease in lipid phosphatase activity (Lopez et al., 2013). In a case study where samples from patients with gastric cancer (GC) and colorectal cancer (CRC) were used, an A7 repeat at the 25th exon of INPP4B was analyzed. An identical frameshift mutation, through deletion of one base, in the A7 repeat region was identified in two CRCs (2/79: 2.5%) and one GC (1/34: 2.9%) patient (Choi et al., 2016).

Implicated in

Note When firstly identified, INPP4B was proposed as a tumor suppressor especially when PTEN was deficient (Gewinner et al., 2009; Kofuji et al., 2015; Vo and Fruman, 2015); however, some studies proved that it could promote carcinogenesis.
  
Entity Melanoma
Note Chi et al. showed that INPP4B is upregulated in melanoma cell lines and human tissues. Even though INPP4B was shown to negatively regulate PI3K/AKT signaling and thus, it was thought to be tumor suppressor, INPP4B was demonstrated to be an oncogenic driver through activation of serum glucocorticoid-regulated kinase 3 (SGK3) and independently of AKT. INPP4B downregulation inhibited cell proliferation and tumor growth in xenograft while its overexpression caused enhanced cell proliferation and anchorage-independent growth of melanocytes (Chi et al., 2015). On the other hand, INPP4B expression was inversely correlated with tumor progression in melanocytic neoplasms (Perez-Lorenzo et al., 2014).
  
  
Entity Colon Cancer
Note INPP4B was demonstrated to be oncogenic and upregulated in human colon cancer cells and tissue. Silencing of INPP4B blocked the activation of AKT and SGK3, and inhibited cell proliferation and tumor growth in xenograft. Overexpression of INPP4B resulted in anchorage-independent growth of normal colon epithelial cells. Also, INPP4B was illustrated to dephosphorylate PTEN in colon cancer cells (Guo et al., 2016).
  
  
Entity Thyroid Cancer
Note Chew et al. showed loss of Innp4b in Pten heterozygous mice leaded to follicular thyroid carcinoma. INPP4B was also demonstrated to inhibit PI3K-C2 Endometrial Cancer α-mediated AKT2 activation in early endosomes in thyroid cancer cells (Chew et al., 2015). INPP4B was downregulated in human thyroid cancer cell lines and samples (Chew et al., 2015; Kofuji et al., 2015).
  
  
Entity Endometrial Cancer
Note INPP4B was demonstrated to be downregulated in samples from patients with endometrial cancer (Kofuji et al., 2015).
  
  
Entity Prostate Cancer
Note Hodgson et al. showed that activation of androgen receptor induced the expression of INPP4B via activation of corepressor, NCOR1, which regulates agonist-bound androgen receptor activity, and decreased the activation of AKT in prostate cancer cell lines. Also, INPP4B expression was shown to be down-regulated in samples from androgen-dependent prostate cancer (Hodgson et al., 2011). Same group also showed that de novo expression of INPP4B suppressed the invasion in vitro and in vivo in human prostate carcinoma cells due to that INPP4B regulated a wide range of genes associated with cell adhesion, extracellular matrix and cytoskeleton. It also inhibited metastases thanks to downregulating metastases-related BIRC5, phosphorylated PKC, expression of PKC in androgen-dependent and -independent manner and PTGS2 (COX-2). Moreover, de novo expressed INPP4B inhibited proinflammatory cytokine CXCL8 (IL-8) and induced PAK6 owing to downregulating PKC (Hodgson et al., 2014). In another study, overexpression of INPP4B in prostate cancer cell line, PC3, inhibited cell proliferation and decreased the levels of phosphorylated AKT (p-AKT), bringing about G1 arrest. Combination of INPP4B overexpression with PARP inhibitor, which arrested the cells in G2/M with an increase in p-AKT level, decreased the p-AKT levels and further inhibited the cell proliferation, suggesting that those combinations could be helpful for treatment of prostate cancer (Ding et al., 2014). INPP4B was also demonstrated to associate with the resistance to chemotherapeutics in prostate cancer. In docetaxel-resistant prostate cancer cell lines, INPP4B was shown to be downregulated. Overexpression of INPP4B resensitized the resistant cell lines towards docetaxel via inhibiting PI3K/AKT activation and expression of the mesenchymal markers fibronectin, N-cadherin, and vimentin, and upregulating the expression level of the epithelial maker E-cadherin (Chen et al., 2016).
  
  
Entity Breast Cancer
Note INPP4B was shown to be expressed in non-proliferative estrogen receptor (ER)-positive cells in normal breast tissue and ER-positive breast cancer cell lines. Nevertheless, ER-negative breast cancer cell lines did not express INPP4B. As a generalization, INPP4B expression was not seen in phosphatase and tensin homolog (PTEN)-null tumors. Down-regulation of INPP4B in ER-positive breast cancer cell lines increased AKT activation, cell proliferation and xenograft tumor growth while overexpression of INPP4B in ER-negative cell lines decreased the activated AKT and anchorage-independent growth (Fedele et al., 2010). Similarly, in triple negative breast cancer cell line, MDA-MB-231, stably overexpression of INPP4B inhibited cell proliferation and arrested the cell cycle at G1 phase through decreasing the level of phosphorylated AKT. By the combinational therapy approach, INPP4B expression was shown to increase the efficacy of poly-(adenosine diphosphate ribose) polymerase (PARP) inhibitor, AG014699 which is a DNA-damaging agent, arresting cell cycle at G2/M transition but could activate PI3K/AKT pathway (Sun et al., 2014). In a review article, Bertucci and Mitchell reported that INPP4B expression was lost in 84% of basal-like breast cancer; INPP4B loss of heterozygosity (LOH) occurs in 55% of triple negative and basal-like cancers, and 60% of BRCA1 mutant tumors as previously shown by Gewinner et al. (Gewinner et al., 2009; Bertucci and Mitchell, 2013). Similarly, INPP4B LOH was observed in 18.1% of Japanese breast cancer patients. Moreover, INPP4B LOH was significantly correlated with estrogen receptor (ER) and progesterone receptor (PR) negativity, higher nuclear grade, PTEN LOH and poorer prognosis (Tokunaga et al., 2016). In a case study where breast cancer samples from 43 patients were used, INPP4B expression was absent or low for 18% of cases. Low expression INPP4B was associated with larger tumor size and higher nuclear grade (Sueta et al., 2014). In another study, INPP4B was shown to prevent AKT activation but trigger the activation of SGK3, which was overexpressed and hyperactivated in breast cancer and caused to proliferation, invasive migration and tumorigenesis in breast cancer in vitro and in vivo models, via production of PI(3)P (Gasser et al., 2014).
  
  
Entity Acute Myeloid Leukemia (AML)
Note Dzneladze et al. showed that high levels of INPP4B in AML patients had poor response to induction therapy, shorter event-free survival and shorter overall survival. In cell culture, overexpression of INPP4B increased the colony formation potential, resulted in resistance to daunorubicin and ionizing radiation and supported phosphatase-dependent and AKT-independent proliferation. Hence, the researchers proposed INPP4B as an independent prognostic marker in AML (Dzneladze et al., 2015). Similarly, INPP4B was shown to be overexpressed in samples from patients with AML in another study. Overexpression of INPP4B in patients with AML resulted in reduced response to chemotherapy, early relapse and poor overall survival as figured out by Dzneladze et al. Moreover, overexpression of an inert variant of INPP4B, which did not display phosphatase activity, did not affect the resistance phenotype in vitro. However, silencing of INPP4B sensitized the AML cell lines towards chemotherapeutics, pointing a phosphoinositide phosphatase function-independent involvement of INPP4B in drug resistance in AML (Rijal et al., 2015).
  
  
Entity Laryngeal Cancer
Note In laryngeal cancer cell line, HEp-2, INPP4B expression was triggered by hypoxia and irradiation. Also, INPP4B overexpression enhanced aerobic glycolysis. It was demonstrated that one of the glycolysis-regulatory gene, hexokinase-2 (HK2) was regulated by INPP4B via AKT-mTOR pathway in this cell line. Silencing of both INPP4B and HK2 sensitized the radioresistant cells toward radiation and chemotherapeutic agents (Min et al., 2013). Moreover, INPP4B was demonstrated to be a marker of radioresistance in HEp-2 cells. INPP4B was shown to be overexpressed in radioresistant HEp-2 cells and that radiation or anticancer drug treatment induced INPP4B expression which was blocked by inhibition of extracellular signal-regulated kinase (ERK). INPP4B overexpression increased the resistance towards radiation and anticancer drugs and depletion of INPP4B re-sensitized the cells (Kim et al., 2012).
  
  
Entity Nasopharyngeal Carcinoma (NPC)
Note NPC is a viral-associated neoplasm where Epstein-Bar virus latent proteins affect multiple signaling cascades. Yuen et al. showed that INPP4B was downregulated in NPC cell lines compared to normal nasopharyngeal epithelial cell lines. The downregulation was demonstrated to become as a result of hypermethylation of the 5'CpG island of INPP4B (Yuen et al., 2014).
  
  
Entity Lung Cancer
Note In a case study where samples were obtained from 180 patients with non-small cell lung cancer subtypes, squamous cell carcinoma (SSC) or adenocarcinoma (ADCA), the ratio of INPP4B copy number was determined as 15% ≤1 copies, 62% 2 copies, and 23% ≥3 copies. Also, 47% displayed loss of loss of INPP4B expression which showed a strong correlation with SCC compared to ADCA (Stjernstrom et al., 2014). In another study, MIR937 which targeted INPP4B by directly binding to 3 UTR of INPP4B was upregulated in lung cancer cell line. Overexpression of miR-937 promoted anchorage-dependent and -independent growth while downregulation prevented these effects. Overexpression of miR-937 was shown to knockdown INPP4B which was proposed as the reason for increased growth rate in lung cancer cell lines (Zhang et al., 2016).
  
  
Entity Bladder Cancer
Note Hsu et al. developed ESR1 (estrogen receptor-α, ERα)--knockout mice to see the effect of ERα in bladder carcinogenesis. They showed that ERα reduced the carcinogen-induced malignant transformation ability. Moreover, ESR1 was demonstrated to control AKT activity via controlling the expression of INPP4B (Hsu et al., 2014).
  
  
Entity Ovarian Cancer; Ovarian Teratomas (OTs) in particular
Note Teratoma is a class of tumors that are composed of ecto-, meso- and endodermal tissues which are all foreign to the site of the origin. OTs are pathogenically activated non-ovulated germ cells-derived ovary tumors that exhibit disorganized pattern of cellular differentiation. Carriers of Rous sarcoma virus (RSV) Tgkd transgene are susceptible to teratomas. Tgkd transgene was demonstrated to be inserted into intergenic region of Inpp4b and Il15. This insertion was shown to affect Inpp4b expression and dysregulation of Akt pathway, promoting progression of ovarian teratomas (Balakrishnan and Chaillet, 2013). In ovarian cancer cells, INPP4B was illustrated to form a complex with BRCA1 and ATR which are the members of DNA repair mechanism. Loss of INPP4B, which was seen in 40% of patients with ovarian cancer studied, disrupted in BRCA1, ATM and ATR protein stabilities, resulting in DNA defects and sensitized the cells towards inhibitors of PARP, a nuclear enzyme sensing DNA single strand breaks and required for base excision repair (Ip et al., 2014).
  
  
Entity Hepatocellular Carcinoma
Note In hepatocellular carcinoma cell lines, MIR765 which directly targeted INPP4B was shown to be upregulated. Upregulation of miR-765 and in turn downregulation of INPP4B increased upregulation of p-AKT, CCND1 (Cyclin D1), and downregulation of p- FOXO3, p21 expression; thus it increased cellular proliferation and tumorigenicity. Downregulation of miR-765 rescued the phenotype in these cell lines via upregulation of INPP4B (Xie et al., 2016).
  
  
Entity Osteoporosis
Disease Osteoporosis is a genetic disease where bone mass is reduced because of dysregulation of osteoclast differentiation and maturation. Ferron et al. proposed Inpp4bα as a regulator of osteoclastogenesis. Inpp4bα was detected to be expressed from early osteoclast differentiation to activation. Moreover, phosphotase-inactivate Inpp4bα triggered the osteoclast activation. Inpp4bα was shown to control intracellular calcium level modulating NFATC1, which is a preosteoclast promoting transcription factor regulating osteoclast maturation, nuclear translocation and activation. Inpp4b-deficient mice displayed increased osteoclast differentiation rate, bringing about decreased bone mass and osteoporosis, and human INPP4B was proposed as a susceptibility locus for osteoporosis. Overall, Inpp4bα was regarded as a negative regulator of osteoclast differentiation (Ferron et al., 2011; Vacher, 2013).
  
  
Entity Multiple Sclerosis (MS)
Disease MS is a neurodegenerative and neuroinflammatory disease causing impairment of nerve conduction. In a genomic study, INPP4B was shown to regulate nerve conduction velocity. Moreover, an INPP4B polymorphism (rs13102150) was associated with MS cohorts (Lemcke et al., 2014).
  

Bibliography

INPP4B: the new kid on the PI3K block
Agoulnik IU, Hodgson MC, Bowden WA, Ittmann MM
Oncotarget 2011 Apr;2(4):321-8
PMID 21487159
 
Role of the inositol polyphosphate-4-phosphatase type II Inpp4b in the generation of ovarian teratomas
Balakrishnan A, Chaillet JR
Dev Biol 2013 Jan 1;373(1):118-29
PMID 23078915
 
Phosphoinositide 3-kinase and INPP4B in human breast cancer
Bertucci MC, Mitchell CA
Ann N Y Acad Sci 2013 Mar;1280:1-5
PMID 23551093
 
Inositol lipid phosphatases in membrane trafficking and human disease
Billcliff PG, Lowe M
Biochem J 2014 Jul 15;461(2):159-75
PMID 24966051
 
INPP4B reverses docetaxel resistance and epithelial-to-mesenchymal transition via the PI3K/Akt signaling pathway in prostate cancer
Chen H, Li H, Chen Q
Biochem Biophys Res Commun 2016 Aug 26;477(3):467-72
PMID 27318090
 
Endosome and INPP4B
Chew CL, Chen M, Pandolfi PP
Oncotarget 2016 Jan 5;7(1):5-6
PMID 26700619
 
INPP4B is upregulated and functions as an oncogenic driver through SGK3 in a subset of melanomas
Chi MN, Guo ST, Wilmott JS, Guo XY, Yan XG, Wang CY, Liu XY, Jin L, Tseng HY, Liu T, Croft A, Hondermarck H, Scolyer RA, Jiang CC, Zhang XD
Oncotarget 2015 Nov 24;6(37):39891-907
PMID 26573229
 
Inactivating Frameshift Mutation of INPP4B Encoding a PI3K Pathway Phosphatase in Gastric and Colorectal Cancers
Choi EJ, Kim MS, Yoo NJ, Lee SH
Pathol Oncol Res 2016 Jul;22(3):653-4
PMID 27068714
 
Functional identification of a novel transcript variant of INPP4B in human colon and breast cancer cells
Croft A, Guo ST, Sherwin S, Farrelly M, Yan XG, Zhang XD, Jiang CC
Biochem Biophys Res Commun 2017 Mar 25;485(1):47-53
PMID 28189677
 
Effects of INPP4B gene transfection combined with PARP inhibitor on castration therapy-resistant prostate cancer cell line, PC3
Ding H, Sun Y, Hou Y, Li L
Urol Oncol 2014 Jul;32(5):720-6
PMID 24837011
 
INPP4B overexpression is associated with poor clinical outcome and therapy resistance in acute myeloid leukemia
Dzneladze I, He R, Woolley JF, Son MH, Sharobim MH, Greenberg SA, Gabra M, Langlois C, Rashid A, Hakem A, Ibrahimova N, Arruda A, Löwenberg B, Valk PJ, Minden MD, Salmena L
Leukemia 2015 Jul;29(7):1485-95
PMID 25736236
 
Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers
Fedele CG, Ooms LM, Ho M, Vieusseux J, O'Toole SA, Millar EK, Lopez-Knowles E, Sriratana A, Gurung R, Baglietto L, Giles GG, Bailey CG, Rasko JE, Shields BJ, Price JT, Majerus PW, Sutherland RL, Tiganis T, McLean CA, Mitchell CA
Proc Natl Acad Sci U S A 2010 Dec 21;107(51):22231-6
PMID 21127264
 
Inositol polyphosphate 4-phosphatase B as a regulator of bone mass in mice and humans
Ferron M, Boudiffa M, Arsenault M, Rached M, Pata M, Giroux S, Elfassihi L, Kisseleva M, Majerus PW, Rousseau F, Vacher J
Cell Metab 2011 Oct 5;14(4):466-77
PMID 21982707
 
Characterization of the murine Inpp4b gene and identification of a novel isoform
Ferron M, Vacher J
Gene 2006 Jul 5;376(1):152-61
PMID 16631325
 
Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling
Gewinner C, Wang ZC, Richardson A, Teruya-Feldstein J, Etemadmoghadam D, Bowtell D, Barretina J, Lin WM, Rameh L, Salmena L, Pandolfi PP, Cantley LC
Cancer Cell 2009 Aug 4;16(2):115-25
PMID 19647222
 
INPP4B is an oncogenic regulator in human colon cancer
Guo ST, Chi MN, Yang RH, Guo XY, Zan LK, Wang CY, Xi YF, Jin L, Croft A, Tseng HY, Yan XG, Farrelly M, Wang FH, Lai F, Wang JF, Li YP, Ackland S, Scott R, Agoulnik IU, Hondermarck H, Thorne RF, Liu T, Zhang XD, Jiang CC
Oncogene 2016 Jun 9;35(23):3049-61
PMID 26411369
 
Decreased expression and androgen regulation of the tumor suppressor gene INPP4B in prostate cancer
Hodgson MC, Shao LJ, Frolov A, Li R, Peterson LE, Ayala G, Ittmann MM, Weigel NL, Agoulnik IU
Cancer Res 2011 Jan 15;71(2):572-82
PMID 21224358
 
Estrogen receptor alpha prevents bladder cancer via INPP4B inhibited akt pathway in vitro and in vivo
Hsu I, Yeh CR, Slavin S, Miyamoto H, Netto GJ, Tsai YC, Muyan M, Wu XR, Messing EM, Guancial EA, Yeh S
Oncotarget 2014 Sep 15;5(17):7917-35
PMID 25277204
 
Loss of INPP4B causes a DNA repair defect through loss of BRCA1, ATM and ATR and can be targeted with PARP inhibitor treatment
Ip LR, Poulogiannis G, Viciano FC, Sasaki J, Kofuji S, Spanswick VJ, Hochhauser D, Hartley JA, Sasaki T, Gewinner CA
Oncotarget 2015 Apr 30;6(12):10548-62
PMID 25868852
 
Identification of inositol polyphosphate 4-phosphatase type II as a novel tumor resistance biomarker in human laryngeal cancer HEp-2 cells
Kim JS, Yun HS, Um HD, Park JK, Lee KH, Kang CM, Lee SJ, Hwang SG
Cancer Biol Ther 2012 Nov;13(13):1307-18
PMID 22895072
 
INPP4B Is a PtdIns(3,4,5)P3 Phosphatase That Can Act as a Tumor Suppressor
Kofuji S, Kimura H, Nakanishi H, Nanjo H, Takasuga S, Liu H, Eguchi S, Nakamura R, Itoh R, Ueno N, Asanuma K, Huang M, Koizumi A, Habuchi T, Yamazaki M, Suzuki A, Sasaki J, Sasaki T
Cancer Discov 2015 Jul;5(7):730-9
PMID 25883023
 
Nerve conduction velocity is regulated by the inositol polyphosphate-4-phosphatase II gene
Lemcke S, Müller S, Möller S, Schillert A, Ziegler A, Cepok-Kauffeld S, Comabella M, Montalban X, Rülicke T, Nandakumar KS, Hemmer B, Holmdahl R, Pahnke J, Ibrahim SM
Am J Pathol 2014 Sep;184(9):2420-9
PMID 25129256
 
In Vivo Role of INPP4B in Tumor and Metastasis Suppression through Regulation of PI3K-AKT Signaling at Endosomes
Li Chew C, Lunardi A, Gulluni F, Ruan DT, Chen M, Salmena L, Nishino M, Papa A, Ng C, Fung J, Clohessy JG, Sasaki J, Sasaki T, Bronson RT, Hirsch E, Pandolfi PP
Cancer Discov 2015 Jul;5(7):740-51
PMID 25883022
 
Determinants of the tumor suppressor INPP4B protein and lipid phosphatase activities
Lopez SM, Hodgson MC, Packianathan C, Bingol-Ozakpinar O, Uras F, Rosen BP, Agoulnik IU
Biochem Biophys Res Commun 2013 Oct 18;440(2):277-82
PMID 24070612
 
INPP4B-mediated tumor resistance is associated with modulation of glucose metabolism via hexokinase 2 regulation in laryngeal cancer cells
Min JW, Kim KI, Kim HA, Kim EK, Noh WC, Jeon HB, Cho DH, Oh JS, Park IC, Hwang SG, Kim JS
Biochem Biophys Res Commun 2013 Oct 11;440(1):137-42
PMID 24051093
 
A tumor suppressor function for the lipid phosphatase INPP4B in melanocytic neoplasms
Perez-Lorenzo R, Gill KZ, Shen CH, Zhao FX, Zheng B, Schulze HJ, Silvers DN, Brunner G, Horst BA
J Invest Dermatol 2014 May;134(5):1359-68
PMID 24288008
 
Inositol polyphosphate 4-phosphatase II (INPP4B) is associated with chemoresistance and poor outcome in AML
Rijal S, Fleming S, Cummings N, Rynkiewicz NK, Ooms LM, Nguyen NY, Teh TC, Avery S, McManus JF, Papenfuss AT, McLean C, Guthridge MA, Mitchell CA, Wei AH
Blood 2015 Apr 30;125(18):2815-24
PMID 25736313
 
Alterations of INPP4B, PIK3CA and pAkt of the PI3K pathway are associated with squamous cell carcinoma of the lung
Stjernström A, Karlsson C, Fernandez OJ, Söderkvist P, Karlsson MG, Thunell LK
Cancer Med 2014 Apr;3(2):337-48
PMID 24500884
 
An integrative analysis of PIK3CA mutation, PTEN, and INPP4B expression in terms of trastuzumab efficacy in HER2-positive breast cancer
Sueta A, Yamamoto Y, Yamamoto-Ibusuki M, Hayashi M, Takeshita T, Yamamoto S, Iwase H
PLoS One 2014 Dec 26;9(12):e116054
PMID 25542038
 
INPP4B overexpression enhances the antitumor efficacy of PARP inhibitor AG014699 in MDA-MB-231 triple-negative breast cancer cells
Sun Y, Ding H, Liu X, Li X, Li L
Tumour Biol 2014 May;35(5):4469-77
PMID 24420152
 
Biological and clinical significance of loss of heterozygosity at the INPP4B gene locus in Japanese breast cancer
Tokunaga E, Yamashita N, Kitao H, Tanaka K, Taketani K, Inoue Y, Saeki H, Oki E, Oda Y, Maehara Y
Breast 2016 Feb;25:62-8
PMID 26577950
 
Inpp4b is a novel negative modulator of osteoclast differentiation and a prognostic locus for human osteoporosis
Vacher J
Ann N Y Acad Sci 2013 Mar;1280:52-4
PMID 23551105
 
INPP4B Is a Tumor Suppressor in the Context of PTEN Deficiency
Vo TT, Fruman DA
Cancer Discov 2015 Jul;5(7):697-700
PMID 26152921
 
Mir-765 promotes cell proliferation by downregulating INPP4B expression in human hepatocellular carcinoma
Xie BH, He X, Hua RX, Zhang B, Tan GS, Xiong SQ, Liu LS, Chen W, Yang JY, Wang XN, Li HP
Cancer Biomark 2016;16(3):405-13
PMID 27062697
 
Epigenetic inactivation of inositol polyphosphate 4-phosphatase B (INPP4B), a regulator of PI3K/AKT signaling pathway in EBV-associated nasopharyngeal carcinoma
Yuen JW, Chung GT, Lun SW, Cheung CC, To KF, Lo KW
PLoS One 2014 Aug 15;9(8):e105163
PMID 25126743
 
miR-937 contributes to the lung cancer cell proliferation by targeting INPP4B
Zhang L, Zeng D, Chen Y, Li N, Lv Y, Li Y, Xu X, Xu G
Life Sci 2016 Jun 15;155:110-5
PMID 27179609
 

Citation

This paper should be referenced as such :
Hasan Huseyin Kazan, Ufuk Gunduz
INPP4B (Inositol Polyphosphate-4-Phosphate Type II B)
Atlas Genet Cytogenet Oncol Haematol. 2018;22(1):8-14.
Free journal version : [ pdf ]   [ DOI ]
On line version : http://AtlasGeneticsOncology.org/Genes/INPP4BID43320ch4q31.html

Other Solid tumors implicated (Data extracted from papers in the Atlas) [ 2 ]
  t(4;4)(p16;q31) KIAA0232/INPP4B
FBXW7/INPP4B (4q31)

External links

Nomenclature
HGNC (Hugo)INPP4B   6075
Cards
AtlasINPP4BID43320ch4q31
Entrez_Gene (NCBI)INPP4B  8821  inositol polyphosphate-4-phosphatase type II B
Aliases
GeneCards (Weizmann)INPP4B
Ensembl hg19 (Hinxton)ENSG00000109452 [Gene_View]
Ensembl hg38 (Hinxton)ENSG00000109452 [Gene_View]  ENSG00000109452 [Sequence]  chr4:142023160-142846535 [Contig_View]  INPP4B [Vega]
ICGC DataPortalENSG00000109452
TCGA cBioPortalINPP4B
AceView (NCBI)INPP4B
Genatlas (Paris)INPP4B
WikiGenes8821
SOURCE (Princeton)INPP4B
Genetics Home Reference (NIH)INPP4B
Genomic and cartography
GoldenPath hg38 (UCSC)INPP4B  -     chr4:142023160-142846535 -  4q31.21   [Description]    (hg38-Dec_2013)
GoldenPath hg19 (UCSC)INPP4B  -     4q31.21   [Description]    (hg19-Feb_2009)
GoldenPathINPP4B - 4q31.21 [CytoView hg19]  INPP4B - 4q31.21 [CytoView hg38]
ImmunoBaseENSG00000109452
Mapping of homologs : NCBIINPP4B [Mapview hg19]  INPP4B [Mapview hg38]
OMIM607494   
Gene and transcription
Genbank (Entrez)AI198719 AK298118 AK300891 AK302936 AY753912
RefSeq transcript (Entrez)NM_001101669 NM_001331040 NM_003866
RefSeq genomic (Entrez)
Consensus coding sequences : CCDS (NCBI)INPP4B
Cluster EST : UnigeneHs.732573 [ NCBI ]
CGAP (NCI)Hs.732573
Alternative Splicing GalleryENSG00000109452
Gene ExpressionINPP4B [ NCBI-GEO ]   INPP4B [ EBI - ARRAY_EXPRESS ]   INPP4B [ SEEK ]   INPP4B [ MEM ]
Gene Expression Viewer (FireBrowse)INPP4B [ Firebrowse - Broad ]
SOURCE (Princeton)Expression in : [Datasets]   [Normal Tissue Atlas]  [carcinoma Classsification]  [NCI60]
GenevestigatorExpression in : [tissues]  [cell-lines]  [cancer]  [perturbations]  
BioGPS (Tissue expression)8821
GTEX Portal (Tissue expression)INPP4B
Human Protein AtlasENSG00000109452-INPP4B [pathology]   [cell]   [tissue]
Protein : pattern, domain, 3D structure
UniProt/SwissProtO15327   [function]  [subcellular_location]  [family_and_domains]  [pathology_and_biotech]  [ptm_processing]  [expression]  [interaction]
NextProtO15327  [Sequence]  [Exons]  [Medical]  [Publications]
With graphics : InterProO15327
Splice isoforms : SwissVarO15327
Catalytic activity : Enzyme3.1.3.66 [ Enzyme-Expasy ]   3.1.3.663.1.3.66 [ IntEnz-EBI ]   3.1.3.66 [ BRENDA ]   3.1.3.66 [ KEGG ]   
PhosPhoSitePlusO15327
Domains : Interpro (EBI)C2_domain_sf   
Domain families : Pfam (Sanger)
Domain families : Pfam (NCBI)
Conserved Domain (NCBI)INPP4B
DMDM Disease mutations8821
Blocks (Seattle)INPP4B
SuperfamilyO15327
Human Protein Atlas [tissue]ENSG00000109452-INPP4B [tissue]
Peptide AtlasO15327
HPRD06322
IPIIPI00022020   IPI00963837   IPI00922726   IPI00965101   IPI00964458   IPI00968221   IPI00029309   IPI00963881   IPI00966726   IPI00967550   IPI00968243   IPI00965363   IPI00965796   
Protein Interaction databases
DIP (DOE-UCLA)O15327
IntAct (EBI)O15327
FunCoupENSG00000109452
BioGRIDINPP4B
STRING (EMBL)INPP4B
ZODIACINPP4B
Ontologies - Pathways
QuickGOO15327
Ontology : AmiGOprotein binding  cytoplasm  cytosol  phosphatidylinositol biosynthetic process  signal transduction  dephosphorylation  phosphatidylinositol-3,4-bisphosphate 4-phosphatase activity  phosphatidylinositol-4,5-bisphosphate 4-phosphatase activity  phosphatidylinositol-3-phosphate biosynthetic process  inositol phosphate metabolic process  
Ontology : EGO-EBIprotein binding  cytoplasm  cytosol  phosphatidylinositol biosynthetic process  signal transduction  dephosphorylation  phosphatidylinositol-3,4-bisphosphate 4-phosphatase activity  phosphatidylinositol-4,5-bisphosphate 4-phosphatase activity  phosphatidylinositol-3-phosphate biosynthetic process  inositol phosphate metabolic process  
Pathways : KEGGInositol phosphate metabolism    Phosphatidylinositol signaling system   
REACTOMEO15327 [protein]
REACTOME PathwaysR-HSA-1855183 [pathway]   
NDEx NetworkINPP4B
Atlas of Cancer Signalling NetworkINPP4B
Wikipedia pathwaysINPP4B
Orthology - Evolution
OrthoDB8821
GeneTree (enSembl)ENSG00000109452
Phylogenetic Trees/Animal Genes : TreeFamINPP4B
HOGENOMO15327
Homologs : HomoloGeneINPP4B
Homology/Alignments : Family Browser (UCSC)INPP4B
Gene fusions - Rearrangements
Fusion : MitelmanFBXW7/INPP4B [4q31.3/4q31.21]  [t(4;4)(q31;q31)]  
Fusion : MitelmanKIAA0232/INPP4B [4p16.1/4q31.21]  [t(4;4)(p16;q31)]  
Fusion PortalFBXW7 4q31.3 INPP4B 4q31.21 LUSC
Fusion PortalKIAA0232 4p16.1 INPP4B 4q31.21 BRCA
Fusion : FusionGDB11100    13221    17495    17496    17497    17498    17499    17500    17501    18568    20965    33080    33643    33958    38756   
8160   
Fusion : Fusion_HubEGFLAM--INPP4B    FBXW7--INPP4B    GLS--INPP4B    GRM8--INPP4B    INPP4B--ALPK2    INPP4B--ARHGAP10    INPP4B--ARHGEF26    INPP4B--C9ORF3    INPP4B--ELL3    INPP4B--FAM120A    INPP4B--FNDC3B    INPP4B--GPX3    INPP4B--IST1    INPP4B--KDM4C    INPP4B--LARP1B   
INPP4B--MAPK10    INPP4B--MCPH1    INPP4B--NIPAL2    INPP4B--NRP1    INPP4B--PALLD    INPP4B--PLCZ1    INPP4B--RNF144A    INPP4B--SLC25A14    INPP4B--TMBIM4    INPP4B--USP38    INPP4B--VPS54    INPP4B--WBSCR17    INPP4B--ZNF330    KIAA0232--INPP4B    MAP9--INPP4B   
MAPK10--INPP4B    PMEL--INPP4B    RNF125--INPP4B    SEC61A1--INPP4B    SH3D19--INPP4B    SKAP2--INPP4B    SYNE2--INPP4B    TMPRSS2--INPP4B   
Fusion : QuiverINPP4B
Polymorphisms : SNP and Copy number variants
NCBI Variation ViewerINPP4B [hg38]
dbSNP Single Nucleotide Polymorphism (NCBI)INPP4B
dbVarINPP4B
ClinVarINPP4B
1000_GenomesINPP4B 
Exome Variant ServerINPP4B
ExAC (Exome Aggregation Consortium)ENSG00000109452
GNOMAD BrowserENSG00000109452
Varsome BrowserINPP4B
Genetic variants : HAPMAP8821
Genomic Variants (DGV)INPP4B [DGVbeta]
DECIPHERINPP4B [patients]   [syndromes]   [variants]   [genes]  
CONAN: Copy Number AnalysisINPP4B 
Mutations
ICGC Data PortalINPP4B 
TCGA Data PortalINPP4B 
Broad Tumor PortalINPP4B
OASIS PortalINPP4B [ Somatic mutations - Copy number]
Somatic Mutations in Cancer : COSMICINPP4B  [overview]  [genome browser]  [tissue]  [distribution]  
Somatic Mutations in Cancer : COSMIC3DINPP4B
Mutations and Diseases : HGMDINPP4B
LOVD (Leiden Open Variation Database)Whole genome datasets
LOVD (Leiden Open Variation Database)LOVD - Leiden Open Variation Database
LOVD (Leiden Open Variation Database)LOVD 3.0 shared installation
BioMutasearch INPP4B
DgiDB (Drug Gene Interaction Database)INPP4B
DoCM (Curated mutations)INPP4B (select the gene name)
CIViC (Clinical Interpretations of Variants in Cancer)INPP4B (select a term)
intoGenINPP4B
NCG5 (London)INPP4B
Cancer3DINPP4B(select the gene name)
Impact of mutations[PolyPhen2] [Provean] [Buck Institute : MutDB] [Mutation Assessor] [Mutanalyser]
Diseases
OMIM607494   
Orphanet
DisGeNETINPP4B
MedgenINPP4B
Genetic Testing Registry INPP4B
NextProtO15327 [Medical]
TSGene8821
GENETestsINPP4B
Target ValidationINPP4B
Huge Navigator INPP4B [HugePedia]
snp3D : Map Gene to Disease8821
BioCentury BCIQINPP4B
ClinGenINPP4B
Clinical trials, drugs, therapy
Chemical/Protein Interactions : CTD8821
Chemical/Pharm GKB GenePA29883
Clinical trialINPP4B
Miscellaneous
canSAR (ICR)INPP4B (select the gene name)
DataMed IndexINPP4B
Probes
Litterature
PubMed60 Pubmed reference(s) in Entrez
GeneRIFsGene References Into Functions (Entrez)
CoreMineINPP4B
EVEXINPP4B
GoPubMedINPP4B
iHOPINPP4B
REVIEW articlesautomatic search in PubMed
Last year publicationsautomatic search in PubMed

Search in all EBI   NCBI

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Wed Nov 13 21:30:33 CET 2019
Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.